Binimetinib CAS 606143-89-9 Raw Materials Powder

Related Attributes

Product details

Binimetinib Powder  Usage and Synthesis.

Binimetinib Powder is an oral antitumor drug used to treat malignancies such as lung, colon, stomach, and pancreatic cancers. It is a tyrosine kinase inhibitor that can inhibit the growth and division of tumor cells, thus achieving the effect of tumor treatment.

Binimetinib CAS 606143-89-9 is a reversible inhibitor of mitogen activated extracellular signal-regulated kinase 1 (MEK1) and MEK2 activity. MEK proteins are upstream regulators of the extracellular signal-associated kinase (ERK) pathway. In vitro, Binimetinib Raw Materials inhibited the phosphating of ERK in a cell-free trial and inhibited BRAF mutinous melanoma cells. Binimetinib is a kinase inhibitor for patients with melanoma, a type of skin cancer.

Binimetinib (MEK162), an oral MEK1 and MEK2 inhibitor, showed an objective remission rate of 10% in patients with NRAS mutations and 5% in patients with BRAF mutations in a phase II clinical study with 71 melanoma patients (30 with NRAS mutations and 41 with BRAF mutations) enrolled in a phase II study in which all enrolled patients were treated with Binimetinib 45 mg/dose twice daily.

Application/Function of Binimetinib Powder.

The main advantage of bemetinib is that it is more effective than pemetinib. Studies have shown that bemetinib can significantly reduce the growth and spread of cancer cells. In addition, bemetinib can significantly reduce chemotherapy drug toxicity and side effects in cancer patients.

By nature, bemetinib is a synthetic, non-natural antibiotic with antibacterial effects. Bemetinib, on the other hand, is a natural penicillin-based drug. The mechanism of action of these two drugs is not identical. In addition, the side effects of pemetinib and bemetinib are different.

When choosing between pimertinib or bemetinib, it is important to consider the different properties of the two. Bimetinib is more antibacterial, while bemetinib has a stronger antiviral effect. In addition, bimetinib can help treat chronic sinusitis and asthma, while bemetinib is more effective in treating allergic sinusitis and asthma. Depending on the patient's specific situation, the doctor may recommend either bimetinib or bemetinib.

Bimetinib and bemetinib have received a lot of attention as the newest pair of anti-cancer drugs. These two drugs have great advantages and can effectively treat cancer. It is hoped that through their widespread use, they can effectively treat cancer and improve people's quality of life.

Pharmacological effects of Binimetinib Powder

Binimetinib (MEK162, ARRY-162, ARRY-438162) is a potent MEK1/2 inhibitor with an IC50 of 12 nM in a cell-free assay.Binimetinib induces G1 cell cycle arrest and apoptosis and induces autophagy in human NSCLC cell lines.Phase 3.

Why choose us?

HRK Factory

About Shipping